Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| XELJANZ (tofacitinib) | XELJANZ (tofacitinib): increased risk of venous thrombo-embolism and increased risk of serious and fatal infections |
||
| Curam (Amoxicillin / Clavulanic acid) | Update on instruction for the preparation of Curam® (Amoxicillin Clavulanic Acid POS - powder for Oral Suspension) bottles |
||
| Ecalta (Anidulafungin) | Ecalta 100mg Powder for Concentrate for Solution for Infusion (Anidulafungin): Solution for Infusion must no longer be frozen |
||
| Hydrochlorothiazide | Hydrochlorothiazide - Risk of non-melanoma skin cancer (basal cell carcinoma, squamous cell carcinoma) |
||
| Depakine (Valproate) | Restrictions on use; pregnancy prevention programme to be put in place. |
||
| Olmepress (Olmesartan) | Restriction of combined use of medicines affecting the renin-angiotensin aldosterone system (RAAS) for medicinal products containing Olmepress (Olmesartan). |
||
| Kyprolis® ( Carfilzomib) | Kyprolis (carfilzomib) – New Safety Information: Risk of Progressive Multifocal Leukoencephalopathy (PML) and Hepatitis B Virus (HBV) Reactivation |
||
| Esbriet® (Pirfenidone) | Important Safety Update on ESBRIET® (pirfenidone) and Drug-Induced Liver Injury (DILI) |
||
| FEGONA® | FEGONA (fingolimod) – New contraindication in pregnant women and in women of childbearing potential not using effective contraception |
||
| Zofran® | Direct Healthcare Professional Communication on the risk of birth defects from the recently published epidemiological studies for Zofran® (Ondansetron) |
Last update date: 21/04/2024 at 10:00 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.